Dihydroxyacetone in a New Formulation – A Powerful Therapeutic Option in VitiligoFesq H. · Brockow K. · Strom K. · Mempel M. · Ring J. · Abeck D.
Department of Dermatology and Allergy, Biederstein, Technical University, Munich, Germany
Background: Most treatment protocols for vitiligo require a long treatment duration and usually do not result in complete repigmentation. Therefore, cosmetically acceptable and easily to handle alternatives are warranted. Objective: To evaluate the properties of dihydroxyacetone (DHA) in a new formulation for the treatment of vitiligo on exposed areas. Methods: We treated 10 patients suffering from vitiligo affecting the face and/or hands with a newly introduced, commercially available self-bronzing cream containing DHA 5%. DHA was applied every second day. Results: The characteristic pigmentation showed very satisfactory cosmetic results in 8 out of 10 patients after 2 weeks of treatment. Conclusion: The new DHA formulation is a practical and well-accepted treatment modality.
Dr. Heike Fesq
Dermatologische Klinik der TU-München
Biedersteiner Strasse 29
D–80802 München (Germany)
Tel. +49 89 4140 0, Fax +49 89 4140 3578, E-Mail firstname.lastname@example.org
Received: Received: September 1, 2000
Accepted after revision: June 6, 2001
Number of Print Pages : 3
Number of Figures : 1, Number of Tables : 0, Number of References : 12
Dermatology (International Journal for Clinical and Investigative Dermatology)
Founded as ‘Dermatologische Zeitschrift’ by Oskar Lassar (1893–1907); Continued by Erich Hoffmann (1908–1938), continued as ‘Dermatologica’ (1939–1991), by Wilhelm Lutz (1939–1958), Rudolf Schuppli (1959–1985)
Official Organ of the Swiss Society for Dermatology and Venereology; Official Organ of the Belgian Royal Society for Dermatology and Venereology
Vol. 203, No. 3, Year 2001 (Cover Date: 2001)
Journal Editor: J.-H. Saurat, Geneva.
ISSN: 1018–8665 (print), 1421–9832 (Online)
For additional information: http://www.karger.com/journals/drm